Atrial Fibrillation Market
Atrial Fibrillation Market - By Devices & Global Region - Market Size, Trends, Opportunity, Forecast 2021-2026Request Sample Request Discount
Atrial fibrillation refers to an irregular and rapid heart rate when the two upper chambers of heart witness chaotic electrical signals. This leads to fast and irregular heart rhythm. The heart rate in atrial fibrillation generally range from 100 to 175 beats a minute.
Ideally, to treat atrial fibrillation, the heart rate and rhythm should be normal. To correct your condition, doctors may be able to reset your heart to its regular rhythm (sinus rhythm) using a procedure called cardioversion.
Electrical cardioversion aids to treat abnormal heart rhythms. This method is also used to treat atrial fibrillation (AFib). In atrial fibrillation, atria of the heart quiver instead of beating the right way. Symptoms of AFib may include shortness of breath, fatigue and a very fast heartbeat.
The global atrial fibrillation market was held at USD 14,604.5 Mn in 2020 and anticipated to reach a value of US$ 40,631.7 Mn by 2026 at a CAGR of 14.4% between 2021 and 2026.
Increased geriatric population and preference for catheter ablation for cardiac arrhythmia treatment contributed to the growth of this market. Lifestyle choices like the prevalence of work from home culture and living in a virtual world lead to increased obesity among children and adults, increasing potential for growth and this market as most heart diseases come from lesser daily movement and inefficient cholesterol management.
Consuming a large amount of alcohol also increases the probability of irregular heart rate, which nudges the market in the forward direction in the coming years.
With the advent of AI, big data and machine learning algorithms, companies are known to change the world and develop devices with algorithms for personalized monitoring and make this market an attractive investment opportunity for the future.
The government is investing in research and testing of the innovative solutions developed by various firms such as implantable pacemakers, refrigerators, and catheters regarded as high-risk medical devices by the US FDA. State regulations are also positively impacting the growth in this market.
Lack of qualified and skilled professionals like cardiologists, technicians & electrophysiologists is a significant factor that can restrict the growth of this market. Shortage in cardiovascular treatment and lesser practically trained professionals who can’t perform procedures on advanced devices negatively impact markets growth.
Pharmaceutical alternatives have also been developing and medications have preferred over atrial fibrillation treatment devices to improve the cost-effectiveness of pharmaceutical drugs and relative effectiveness.
- Surgical Devices
- Maze Surgery
- Catheter Ablation
- Radiofrequency Catheter Ablation
- Conventional RF Ablation Catheters
- Irrigated-tip RF Ablation Catheters
- Microwave Based Catheter Ablation
- Laser Based Catheter Ablation
- Navigational Advanced Mapping Accessories
- Non-Surgical Devices
- Electric Cardioversion
- Diagnostic Catheters
- Conventional Diagnostic Catheters
- Fixed Diagnostic Catheters
- Steerable Diagnostic Catheters
- Advanced Diagnostic Catheters
- Mapping and Recording Systems
- Cardiac Monitors
- Access Devices
- Left Atrial Appendage and Closure Devices
- Intracardiac Echocardiography (ICE) Systems
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Latin America-Middle East-Africa
- South Africa
In terms of region, the North America region generated the highest market value in 2020. This is due to the refined medical care framework and the high reception pace of exceptionally cutting-edge innovations in North American nations like the U.S., Canada, and Mexico. Additionally, emerging markets, for example, Mexico, have seen critical ventures by the public authority and merchants.
In addition, Asia-Pacific is anticipated to be the quickest developing region during the forecast period because of its large population base and distinctive age groups being powerless to cardiovascular sicknesses. The interest for AF gadgets is relied upon to help because of progress in medical care foundation and consumption in the rising business sectors (like India and China) to meet the clinical necessities in these countries. Japan and China have a huge portion of geriatric urban population which are more prone cardiac malfunctions, and will make the devices in this market more relevant and a lucrative opportunity.
- Bristol-Myers Squibb,
- Daiichi Sankyo,
- Pierre Fabre,
- Gilead Sciences,
- ARCA Biopharma,
- HUYA Biosciences,
- Janssen Pharmaceuticals,
- Boehringer Ingelheim,
- 17-MAY-2021-Finerenone may delay onset of AFib in patients with chronic kidney disease, diabetes- Patients with chronic kidney disease and Type 2 diabetes who took the experimental drug finerenone were about 30% less likely to develop the heart rhythm disorder atrial fibrillation (AFib) than those taking a placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
- May 2020, CardioFocus, Inc. received the U.S. Food and Drug Administration approval for the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.
Custom Research Requirement? Questions to ask?Get in touch
Custom Research requirement.